The big issues are still the rising cost of coverage and the impact that rising costs have on health plan membership
Premiums for employer-sponsored health insurance rose to $13,375 annually for family coverage this year-with employees on average paying $3,515 and employers paying $9,860, according to the 2009 Employer Health Benefits Survey released by the Kaiser Family Foundation and the Health Research & Educational Trust. According to Jordan Battani, principal at CSC, a consulting and outsourcing company, in Falls Church, Va., for managed care executives, the big issues are still the rising cost of coverage and the impact that rising costs have on health plan membership. “Although the increases this year are lower than in preceding years-they still far surpass general inflation-which was negative,” Battani says. “As general economic conditions decline, the ability of individual consumers and employer purchasers to withstand price increases erodes, and they may exit the market.”Another factor, particularly as it relates to employer purchasers who compete in an increasingly global economy, is that extraordinary costs in the market place U.S. employers at a competitive disadvantage, according to Battani.“Again, these employer purchasers may decide to exit the market-either by dropping employer sponsored coverage, or in a more dramatic fashion, by abandoning the U.S. labor force entirely,” Battani says.Employers and managed care executives must continue to focus on addressing the underlying costs of healthcare, and the underlying inflation that drives premium. Of particular importance is the direct and indirect healthcare costs associated with long term chronic disease, Battani says. Managed care executives should make efforts to support these workplace programs, she says, and perhaps design value-added services for employers that will assist them in promoting expanding and maintaining them.“At the same time, it is probably time to re-examine the strategy of shifting costs to consumers, either through high-deductible plans or in the form of copays and coinsurance,” Battani says. “These strategies may have been effective in moderating the growth of employer premium costs, but this study suggests that for many consumers they are proving onerous or unsupportable on an individual basis.”
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
Positive Pipeline Updates for Friedreich’s Ataxia
October 24th 2024After experiencing setbacks, PTC reported positive results for vatiquinone, its selective inhibitor of 15-Lipoxygenase (15-LO) enzyme, regulator of the energetic and oxidative stress pathways that are disrupted in Friedreich ataxia
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
Positive Pipeline Updates for Friedreich’s Ataxia
October 24th 2024After experiencing setbacks, PTC reported positive results for vatiquinone, its selective inhibitor of 15-Lipoxygenase (15-LO) enzyme, regulator of the energetic and oxidative stress pathways that are disrupted in Friedreich ataxia
Read More
2 Commerce Drive
Cranbury, NJ 08512